HUE068199T2 - Hatásos és szelektív vegyületek mint szerotonin 1B receptor modulátorok - Google Patents

Hatásos és szelektív vegyületek mint szerotonin 1B receptor modulátorok

Info

Publication number
HUE068199T2
HUE068199T2 HUE21789678A HUE21789678A HUE068199T2 HU E068199 T2 HUE068199 T2 HU E068199T2 HU E21789678 A HUE21789678 A HU E21789678A HU E21789678 A HUE21789678 A HU E21789678A HU E068199 T2 HUE068199 T2 HU E068199T2
Authority
HU
Hungary
Prior art keywords
serotonin
potent
receptor modulators
selective compounds
selective
Prior art date
Application number
HUE21789678A
Other languages
English (en)
Hungarian (hu)
Inventor
Palomino Laria Julio Castro-
Gomez Juan Alberto Camacho
Risueno Ruth Munoz
Lise Clement-Demange
Original Assignee
Leukos Biotech S L
Fundacio Inst De Recerca Contra La Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukos Biotech S L, Fundacio Inst De Recerca Contra La Leucemia Josep Carreras filed Critical Leukos Biotech S L
Publication of HUE068199T2 publication Critical patent/HUE068199T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE21789678A 2020-10-08 2021-10-07 Hatásos és szelektív vegyületek mint szerotonin 1B receptor modulátorok HUE068199T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20382888 2020-10-08

Publications (1)

Publication Number Publication Date
HUE068199T2 true HUE068199T2 (hu) 2024-12-28

Family

ID=73030029

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21789678A HUE068199T2 (hu) 2020-10-08 2021-10-07 Hatásos és szelektív vegyületek mint szerotonin 1B receptor modulátorok

Country Status (21)

Country Link
US (2) US12540133B2 (enExample)
EP (2) EP4225753B1 (enExample)
JP (1) JP7687636B2 (enExample)
KR (1) KR20230107566A (enExample)
CN (1) CN116635390B (enExample)
AU (1) AU2021356114A1 (enExample)
CA (1) CA3194700A1 (enExample)
CL (1) CL2023001021A1 (enExample)
DK (1) DK4225753T3 (enExample)
ES (1) ES2985416T3 (enExample)
FI (1) FI4225753T3 (enExample)
HR (1) HRP20241184T1 (enExample)
HU (1) HUE068199T2 (enExample)
IL (1) IL301806B2 (enExample)
LT (1) LT4225753T (enExample)
MX (1) MX2023004116A (enExample)
PL (1) PL4225753T3 (enExample)
PT (1) PT4225753T (enExample)
RS (1) RS65956B1 (enExample)
SI (1) SI4225753T1 (enExample)
WO (1) WO2022074103A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102993831B1 (ko) 2020-10-08 2026-07-23 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
CN117903116A (zh) * 2021-08-27 2024-04-19 杭州阿诺生物医药科技有限公司 细胞周期蛋白k降解剂
JP2026521568A (ja) 2023-06-16 2026-06-30 レウコス バイオテク ソシエダッド リミターダ 5-htr1b調節因子を用いた固形腫瘍の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
SK492001A3 (en) 1998-07-20 2001-08-06 Merck Patent Gmbh Biphenyl derivatives
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Also Published As

Publication number Publication date
US20260138974A1 (en) 2026-05-21
US20240166639A1 (en) 2024-05-23
WO2022074103A1 (en) 2022-04-14
KR20230107566A (ko) 2023-07-17
CL2023001021A1 (es) 2023-11-24
FI4225753T3 (fi) 2024-08-29
DK4225753T3 (da) 2024-08-19
CN116635390A (zh) 2023-08-22
CN116635390B (zh) 2026-03-27
ES2985416T3 (es) 2024-11-05
CA3194700A1 (en) 2022-04-14
JP7687636B2 (ja) 2025-06-03
LT4225753T (lt) 2024-08-26
IL301806B1 (en) 2026-01-01
US12540133B2 (en) 2026-02-03
EP4445901A3 (en) 2024-12-04
PT4225753T (pt) 2024-08-30
HRP20241184T1 (hr) 2024-11-22
EP4445901A2 (en) 2024-10-16
SI4225753T1 (sl) 2024-10-30
EP4225753A1 (en) 2023-08-16
IL301806A (en) 2023-05-01
AU2021356114A9 (en) 2024-09-12
IL301806B2 (en) 2026-05-01
PL4225753T3 (pl) 2024-11-18
EP4225753B1 (en) 2024-07-31
JP2023547346A (ja) 2023-11-10
AU2021356114A1 (en) 2023-05-18
RS65956B1 (sr) 2024-10-31
MX2023004116A (es) 2023-06-13

Similar Documents

Publication Publication Date Title
IL274321A (en) Bridged bicyclic compounds as farnesoid X receptor modulators
IL295598A (en) Selective estrogen receptor antagonists
LT4225753T (lt) Stiprūs ir selektyvūs junginiai, kaip serotonino 1b receptoriaus moduliatoriai
EP3512842A4 (en) INDOLDER DERIVATIVES AS A DEGRADOR OF THE ESTROGEN RECEPTOR
IL274322A (en) Spirocyclic compounds as paranoid X receptor modulators
IL279990B1 (en) Selective estrogen receptor antagonists
IL285630A (en) Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
IL268319A (en) Benzothiophene estrogen receptor modulators
IL274320A (en) Spirocyclic alkene compounds as paranoid X receptor modulators
IL297675B1 (en) Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators
IL278045A (en) History of pyrazo-tetrahydroisoquinoline as a dopamine D1 receptor with positive modulators
EP3595661A4 (en) POLYCYCLIC AMINES USED AS MODULATORS OF OPIOID RECEPTOR
IL291523A (en) Estrogen-related alpha receptor modulators (erraalpha)
IL289510A (en) Estrogen-related receptor modulators (erralpha)
IL307453A (en) Opioid receptor modulators
ZA201904333B (en) Adenosine a3 receptor modulators
IL311640A (en) Bicyclic amine history as gabaa α5 receptor modulators
SG11202108798XA (en) Substituted amide compounds useful as farnesoid x receptor modulators
EP4200287A4 (en) SEROTONIN RECEPTOR MODULATORS
HK40034433A (en) Bridged bicyclic compounds as farnesoid x receptor modulators
HK40035058A (en) Spirocyclic compounds as farnesoid x receptor modulators
HK40065843A (en) Substituted bicyclic compounds as farnesoid x receptor modulators
HK40107649A (en) Opioid receptor modulators
LT3784215T (lt) Minkšto gelio kapsulė, apimanti selektyvų estrogenų receptorių moduliatorių
HK40018940A (en) Benzothiophene estrogen receptor modulators